Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA RNA Based Therapeutic Market, by Type
1.4.2 LAMEA RNA Based Therapeutic Market, by Application
1.4.3 LAMEA RNA Based Therapeutic Market, by End User
1.4.4 LAMEA RNA Based Therapeutic Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2022, Jan) Leading Players
Chapter 4. LAMEA RNA Based Therapeutic Market by Type
4.1 LAMEA RNA Antisense Market by Country
4.2 LAMEA RNA Interference (RNAi) Market by Country
Chapter 5. LAMEA RNA Based Therapeutic Market by Application
5.1 LAMEA Genetic disorders Market by Country
5.2 LAMEA Auto immune disorders Market by Country
Chapter 6. LAMEA RNA Based Therapeutic Market by End User
6.1 LAMEA Research Institutes Market by Country
6.2 LAMEA Hospitals & Clinics Market by Country
Chapter 7. LAMEA RNA Based Therapeutic Market by Country
7.1 Brazil RNA Based Therapeutic Market
7.1.1 Brazil RNA Based Therapeutic Market by Type
7.1.2 Brazil RNA Based Therapeutic Market by Application
7.1.3 Brazil RNA Based Therapeutic Market by End User
7.2 Argentina RNA Based Therapeutic Market
7.2.1 Argentina RNA Based Therapeutic Market by Type
7.2.2 Argentina RNA Based Therapeutic Market by Application
7.2.3 Argentina RNA Based Therapeutic Market by End User
7.3 UAE RNA Based Therapeutic Market
7.3.1 UAE RNA Based Therapeutic Market by Type
7.3.2 UAE RNA Based Therapeutic Market by Application
7.3.3 UAE RNA Based Therapeutic Market by End User
7.4 Saudi Arabia RNA Based Therapeutic Market
7.4.1 Saudi Arabia RNA Based Therapeutic Market by Type
7.4.2 Saudi Arabia RNA Based Therapeutic Market by Application
7.4.3 Saudi Arabia RNA Based Therapeutic Market by End User
7.5 South Africa RNA Based Therapeutic Market
7.5.1 South Africa RNA Based Therapeutic Market by Type
7.5.2 South Africa RNA Based Therapeutic Market by Application
7.5.3 South Africa RNA Based Therapeutic Market by End User
7.6 Nigeria RNA Based Therapeutic Market
7.6.1 Nigeria RNA Based Therapeutic Market by Type
7.6.2 Nigeria RNA Based Therapeutic Market by Application
7.6.3 Nigeria RNA Based Therapeutic Market by End User
7.7 Rest of LAMEA RNA Based Therapeutic Market
7.7.1 Rest of LAMEA RNA Based Therapeutic Market by Type
7.7.2 Rest of LAMEA RNA Based Therapeutic Market by Application
7.7.3 Rest of LAMEA RNA Based Therapeutic Market by End User
Chapter 8. Company Profiles
8.1 Arbutus Biopharma Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisitions, Mergers and Joint Ventures:
8.2 Arrowhead Pharmaceuticals, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Benitec Biopharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.4 Alnylam Pharmaceuticals, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expense
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Approvals and Trials:
8.5 Sanofi S.A. (Sanofi Genzyme)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Biogen, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.7 Gradalis, Inc.
8.7.1 Company Overview
8.8 Ionis Pharmaceuticals, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Sarepta Therapeutics, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Research & Development Expenses
8.9.4 Recent strategies and developments:
8.9.4.1 Partnerships, Collaborations, and Agreements:
8.10. Silence Therapeutics Plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
Unique Offerings 